Employers › Biocraft Laboratories
Recordkeeping fees per participant · Teva Pharmaceuticals Retirement Savings Plan · plan year 2024
$56.82
Higher than 90% of the 790 plans over $1B that report it.
= $544,862 / 9,589
Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251008084806NAL0003136883001, received 2025-10-08
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251008084806NAL0003136883001, received 2025-10-08
Percentiles compare this plan with the Schedule H plans over $1B in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-10-08.
Administrative expenses excluding investment management, per participant
$58.11
Higher than 69% of the 1,045 plans over $1B that report it.
= $557,252 / 9,589
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251008084806NAL0003136883001, received 2025-10-08
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251008084806NAL0003136883001, received 2025-10-08
Administrative expenses per participant
$94.24
Higher than 67% of the 1,076 plans over $1B that report it.
= $903,713 / 9,589
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251008084806NAL0003136883001, received 2025-10-08
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251008084806NAL0003136883001, received 2025-10-08
Administrative expenses as a share of assets
0.039%
Higher than 42% of the 1,076 plans over $1B that report it.
= $903,713 / $2,334,055,601
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251008084806NAL0003136883001, received 2025-10-08
assets_eoy: Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251008084806NAL0003136883001, received 2025-10-08
Employer contributions per participant
$6,793
Higher than 81% of the 1,135 plans over $1B that report it.
= $65,141,405 / 9,589
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251008084806NAL0003136883001, received 2025-10-08
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251008084806NAL0003136883001, received 2025-10-08
Employer share of total contributions
45.2%
Higher than 86% of the 1,135 plans over $1B that report it.
= $65,141,405 / $144,084,692
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251008084806NAL0003136883001, received 2025-10-08
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251008084806NAL0003136883001, received 2025-10-08
Plan terms are described in Biocraft Laboratories Inc's SEC filings: Form 10-K filed 1995-06-29. No term could be quoted from them with the required precision.
2F ERISA 404(c) plan · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2S pre-approved plan document · 2T default investment (QDIA) · 3H controlled-group sponsor · 2E profit-sharing · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20251008084806NAL0003136883001, received 2025-10-08
| Field | Value | Source |
|---|---|---|
| Plan sponsor | TEVA PHARMACEUTICALS USA, INC. | Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Plan name | TEVA PHARMACEUTICALS RETIREMENT SAVINGS PLAN | Form 5500, line 1a; PLAN_NAME pos 16; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Sponsor EIN / plan number | 22-1734359 / 004 | Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Plan type | single-employer | Form 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Sponsor location | PARSIPPANY, NJ | Form 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Industry (business code) | 325410, Manufacturing | Form 5500, line 2d; BUSINESS_CODE pos 46; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Plan year | 2024-01-01 to 2024-12-31 | Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Filing received | 2025-10-08 | Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Final filing | no | Form 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Amended filing | no | Form 5500, Part I line B; AMENDED_IND pos 7; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Participants, beginning of year | 10,122 | Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Active participants | 5,037 | Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Participants, end of year | 9,752 | Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Participants with an account balance | 9,589 | Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Total assets, beginning of year | $2,140,275,364 | Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Total assets, end of year | $2,334,055,601 | Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Net assets, end of year | $2,334,054,031 | Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Total income | $446,235,486 | Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Net income | $193,784,527 | Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Employer contributions | $65,141,405 | Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Participant contributions | $64,055,323 | Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Other contributions (incl. rollovers) | $14,887,964 | Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Total contributions | $144,084,692 | Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Benefit payments | $251,473,542 | Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Total expenses (incl. benefit payments) | $252,450,959 | Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Total administrative expenses | $903,713 | Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Contract administrator fees | $0 | Schedule H, line 2i(2); CONTRACT_ADMIN_FEES_AMT pos 106; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Recordkeeping fees | $544,862 | Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| IQPA audit fees | $0 | Schedule H, line 2i(4); IQPA_AUDIT_FEES_AMT pos 161; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Investment advisory and management fees | $346,461 | Schedule H, line 2i(5); INVST_MGMT_FEES_AMT pos 107; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Administrative expenses excluding investment management | $557,252 | derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Held in master trusts | $0 | Schedule H, line 1c(11) col (b); INT_MASTER_TR_EOY_AMT pos 53; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Held in common/collective trusts | $2,178,396,812 | Schedule H, line 1c(9) col (b); INT_COMMON_TR_EOY_AMT pos 51; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Held in mutual funds | $105,370,921 | Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20251008084806NAL0003136883001, received 2025-10-08 |
| Independent auditor | TORRILLO & ASSOCIATES, LLC | Schedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20251008084806NAL0003136883001, received 2025-10-08 |
Position = column in the DOL layout for form year 2024. Filing 20251008084806NAL0003136883001, received 2025-10-08.
| Provider | Relationship | Service codes | Direct compensation | Indirect |
|---|---|---|---|---|
| FIDELITY INVESTMENTS INSTITUTIONALrecordkeeper | RECORDKEEPER | 37 Participant loan processing; 60 Sub-transfer agency fees; 64 Recordkeeping fees; 65 Account maintenance fees | $544,862 | yes |
| AON INVESTMENTS USA INC | INVESTMENT ADVISOR | 27 Investment advisory (plan) | $346,461 | no |
| AON CONSULTING, INC. | CONSULTING | 16 Consulting (general) | $12,390 | no |
Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20251008084806NAL0003136883001, received 2025-10-08.
| Figure | 2023 | 2024 | Change |
|---|---|---|---|
| Total assets | $2,140,275,364 | $2,334,055,601 | 9.1% |
| Participants with a balance | 9,958 | 9,589 | -3.7% |
| Administrative expenses | $879,951 | $903,713 | 2.7% |
| Recordkeeping fees per participant | $55.26 | $56.82 | 2.8% |
| Employer contributions | $63,166,865 | $65,141,405 | 3.1% |
Prior filing 20241008145958NAL0030292400001, received 2024-10-08; the plan years are contiguous.
Sponsor name as filed: TEVA PHARMACEUTICALS USA, INC.; SEC registrant: BIOCRAFT LABORATORIES INC (CIK 763043, matched by EIN).